Sernova Corp.

TSX:SVA.TO

Biotechnology

Healthcare
$0.14 -5.88%

-$0.01 today

Market cap
$50.98M
Beta
0.66
P/E (TTM)
-4.7
EPS (TTM)
-$0.03
52W Low $0.12High $0.21

Volume 0.55M

Average 0.12M

SVA.TO Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Sernova Corp.TSX: SVA.TO

Depreciation & Amortization · Q2 FY2026 · quarter ended Apr 2026

Depreciation & amortization declines year over year

Q2 FY2026 depreciation & amortization of CA$4.43K fell 90.7% year over year, behind the -40.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -8.0% a year.

Context

  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -90.7% toward the trailing-twelve-month pace of -40.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterApr 2026
CA$4.43K+0.0% QoQ
Last fiscal yearOct 2025
CA$342.59K-16.5% YoY
LTMApr 2026
CA$256.13K-40.2% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-90.7%——
1 year-16.5%——
3-year CAGR-8.0%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

CAD · from the income statement

Latest · FY2025
342.59K CAD
Year-over-year change
-16.5%
4-year CAGR
+6.4%

Depreciation & Amortization vs competitors

How SVA.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -40.2% is the lowest of 2, against a peer median of -25.5%.
  • Over three fiscal years its annual growth of -8.0% compares with a peer median of +91.9%.
SVA.TO Competitors
Depreciation & Amortization for SVA.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SVA.TOSernova Corp.LTM Apr 2026CA$256.13K CAD-40.2%-8.0%—
BCT.TOBriaCell Therapeutics Corp.LTM Apr 2026$112.91K USD-25.5%+91.9%—
Peer median (excluding SVA.TO) —-25.5%+91.9%—

Competitors are the stored peer set for SVA.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Oct 2021
FY2022
Oct 2022
FY2023
Oct 2023
FY2024
Oct 2024
FY2025
Oct 2025
Revenue00000
Cost of Revenue267.2K440K445.55K540.28K342.59K
Gross Profit(267.2K)(440K)(445.55K)(540.28K)(342.59K)
Gross Margin—————
Research & Development4.64M16.9M32.26M22.36M7.28M
Selling, General & Admin2.29M7.83M8.46M8.97M7.5M
Operating Expenses6.94M24.75M41.13M31.84M14.78M
Depreciation & Amortization267.2K440K308.49K410.53K342.59K
EBITDA(6.6M)(24.54M)(40.19M)(31.25M)(14.74M)
EBITDA Margin—————
Operating Income(6.87M)(24.18M)(41.13M)(31.84M)(15.12M)
Operating Margin—————
Interest Income70.55K577.29K1.5M388.39K25.63K
Interest Expense58.37K118K32.08K586.86K754.81K
Other Income / Expenses1.09M1.01M1.5M(347.04K)(711.01K)
Income Before Tax(6.97M)(24.42M)(39.63M)(32.19M)(15.84M)
Pre-Tax Margin—————
Income Tax Expense58.37K118K(629.02K)7K(92.19K)
Net Income(7.02M)(24.54M)(39M)(32.19M)(15.74M)
Net Margin—————
EPS (Basic)(0.03)(0.09)(0.13)(0.10)(0.05)
EPS (Diluted)(0.03)(0.09)(0.13)(0.10)(0.05)
Weighted Avg Shares245.52M273.59M303.33M306.96M328.29M
Weighted Avg Shares (Diluted)245.52M273.59M303.33M306.95M328.29M

Sernova Corp.

TSX:SVA.TO

Intrinsic Alpha fair value

Locked

Current Price

$0.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.